Wormser GP et al. Clinical Infectious Diseases 2006;43:1089-1134. Republished with permission from University of Chicago Press. © 2006 by the Infectious Diseases Society of America. All rights reserved. | |
Table Four: Selected antimicrobials, drug regimens, or other modalities not recommended for the treatment of Lyme disease. |
| Doses of antimicrobials far in excess of those provided in tables 2 and 3 |
| Multiple, repeated courses of antimicrobials for the same episode of Lyme disease or a duration of antimicrobial therapy prolonged far in excess of that shown in table 3 |
| Combination antimicrobial therapy |
| Pulsed-dosing (i.e., antibiotic therapy on some days but not on other days) |
| First-generation cephalosporins, benzathine penicillin G, fluoroquinolones, carbapenems, vancomycin, metronidazole, tinidazole, trimethoprim-sulfamethoxazole, amantadine, ketolides, isoniazid, or fluconazole |
| Empirical antibabesiosis therapy in the absence of documentation of active babesiosis |
| Anti-Bartonella therapies |
| Hyperbaric oxygen therapy |
| Fever therapy (with or without malaria induction) |
| Intravenous immunoglobulin |
| Ozone |
| Cholestyramine |
| Intravenous hydrogen peroxide |
| Vitamins or nutritional managements |
| Magnesium or bismuth injections |